Standard Biotools (LAB) Net Income towards Common Stockholders Growth (3y) (2013 - 2026)
Standard Biotools (LAB) Net Income towards Common Stockholders Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 187.02 Bn | 179.73 Bn | 6.27 Bn | -6.51% |
| 2 | Stryker | 132.13 Bn | 129.26 Bn | 3.81 Bn | 7.96% |
| 3 | Medtronic | 111.43 Bn | 102.21 Bn | 6.41 Bn | 1.93% |
| 4 | Boston Scientific | 68.97 Bn | 67.52 Bn | 3.61 Bn | 64.73% |
| 5 | Edwards Lifesciences | 48.31 Bn | 44.64 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.91 Bn | 27.79 Bn | 750.30 Mn | 60.12% |
| 7 | GE HealthCare Technologies | 28.86 Bn | 26.58 Bn | 1.98 Bn | 29.56% |
| 8 | Smith & Nephew | 28.12 Bn | 27.54 Bn | - | - |
| 9 | Koninklijke Philips | 24.33 Bn | 21.29 Bn | 2.01 Bn | 496.01% |
| 10 | Standard Biotools | 302.22 Mn | -152.96 Mn | 11.31 Mn | 118.37% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 118.37% |
| Dec 31, 2025 | -26.29% |
| Sep 30, 2025 | -5.64% |
| Jun 30, 2025 | 34.73% |
| Mar 31, 2025 | 67.32% |
| Sep 30, 2024 | 23.94% |
| Jun 30, 2024 | 10.88% |
| Mar 31, 2024 | -19.58% |
| Dec 31, 2023 | 40.65% |
| Sep 30, 2023 | -51.59% |
| Jun 30, 2023 | -9.40% |
| Mar 31, 2023 | -1.81% |
| Dec 31, 2022 | 141.45% |
| Sep 30, 2022 | -31.68% |
| Jun 30, 2022 | -66.56% |
| Mar 31, 2022 | -44.16% |
| Sep 30, 2021 | -50.10% |
| Jun 30, 2021 | -30.33% |
| Mar 31, 2021 | -12.41% |
| Dec 31, 2020 | -19.97% |